Diabetes Care
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Published online May 16, 2008
Diabetes Care 31:1502-1509, 2008
DOI: 10.2337/dc08-0118
© 2008 by the American Diabetes Association
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
dc08-0118v1
31/8/1502    most recent
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Chew, G. T.
Right arrow Articles by Currie, P. J.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chew, G. T.
Right arrow Articles by Currie, P. J.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Clinical Care/Education/Nutrition/Psychosocial Research
Original Research

Hemodynamic Effects of Fenofibrate and Coenzyme Q10 in Type 2 Diabetic Subjects With Left Ventricular Diastolic Dysfunction

Gerard T. Chew, MD1, Gerald F. Watts, DSC1, Timothy M.E. Davis, DPHIL1, Bronwyn G.A. Stuckey, MD1,2, Lawrence J. Beilin, MD1, Peter L. Thompson, MD1, Valerie Burke, MD1 and Philip J. Currie, MD3

1 School of Medicine and Pharmacology, University of Western Australia, Perth, Western Australia, Australia
2 Keogh Institute for Medical Research, Nedlands, Western Australia, Australia
3 Echo Services, Nedlands, Western Australia, Australia

Corresponding author: Professor Gerald F. Watts, gwatts{at}meddent.uwa.edu.au

OBJECTIVE—To investigate the effects of fenofibrate and coenzyme Q10 (CoQ) on diastolic function, ambulatory blood pressure (ABP), and heart rate (HR) in type 2 diabetic subjects with left ventricular diastolic dysfunction (LVDD).

RESEARCH DESIGN AND METHODS—We randomized, double-blind, 74 subjects to fenofibrate 160 mg daily, CoQ 200 mg daily, fenofibrate 160 mg plus CoQ 200 mg daily, or matching placebo for 6 months. Echocardiography (including tissue Doppler imaging) and 24-h ABP and HR monitoring were performed pre- and postintervention.

RESULTS—Neither fenofibrate nor CoQ, alone or in combination, altered early diastolic mitral annular myocardial relaxation velocity (E'), early-to-late mitral inflow velocity ratio (E/A), deceleration time, isovolumic relaxation time, or the ratio of early mitral flow velocity to early diastolic mitral annular myocardial relaxation velocity (E/E') compared with placebo (P > 0.05). Fenofibrate and CoQ interactively (P = 0.001) lowered 24-h systolic blood pressure (–3.4 ± 0.09 mmHg, P = 0.010), with a prominent nocturnal effect (–5.7 ± 1.5 mmHg, P = 0.006). Fenofibrate (–1.3 ± 0.5 mmHg, P = 0.013) and CoQ (–2.2 ± 0.5 mmHg, P < 0.001) independently lowered 24-h diastolic blood pressure. Fenofibrate reduced 24-h HR (–3.3 ± 0.5 beats/min, P < 0.001), but CoQ had no effect on HR.

CONCLUSIONS—In type 2 diabetic subjects with LVDD, neither fenofibrate nor CoQ, alone or in combination, improved diastolic function significantly. However, fenofibrate and CoQ independently and interactively lowered 24-h blood pressure, and fenofibrate alone reduced 24-h HR.


Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 2008 by the American Diabetes Association.